Latest Period
Q1 2026
Security Snapshot
RIGEL PHARMACEUTICALS INC - Common Stock, par value $0.001 per share (RIGL) Institutional Ownership
CUSIP: 766559702
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
148
Shares (Excl. Options)
15,871,693
Price
$27.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- RIGL on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 15,871,693
- Total 13F value
- $428,893,659
- Portfolio coverage rank
- 0%
- Share change
- -158,973
- Value change
- -$17,595,270
- Number of holders
- 148
- Shares outstanding
- 18,470,418
- SEC-reported price per share
- $29.17
- Insider filing price
- $29.17
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RIGL - RIGEL PHARMACEUTICALS INC - Common Stock, par value $0.001 per share is tracked under CUSIP 766559702.
- 148 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 185 to 148 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $688,576,820 to $428,893,659.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 148 institutions filings for Q1 2026.
Security key
766559702
Latest holder period
Q1 2026
13F holders
148
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
RIGL full holder history
RIGEL PHARMACEUTICALS INC SEC filings
RIGEL PHARMACEUTICALS INC company facts
RIGEL PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 766559702:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RIGL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.7% | -22% | $26,340,596 | -$6,978,323 | 1,381,983 | -21% | BlackRock, Inc. | 31 Mar 2025 |
| ARMISTICE CAPITAL, LLC | 6.9% | -19% | $36,774,400 | -$6,780,280 | 1,280,000 | -16% | Armistice Capital, LLC | 31 Mar 2026 |
| STATE STREET CORP | 6% | $45,645,858 | 1,091,223 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| Soleus Capital Master Fund, L.P. | 5.2% | +38% | $27,813,743 | +$8,905,237 | 968,108 | +47% | Soleus Capital Master Fund, L.P. | 06 May 2026 |
| MORGAN STANLEY | 0.7% | $3,297,817 | 116,406 | Morgan Stanley | 30 Sep 2025 | |||
| Invesco Ltd. | 0% | $122,918 | 6,449 | Invesco Ltd. | 31 Dec 2024 |
As of 31 Mar 2026, 148 institutional investors reported holding 15,871,693 shares of RIGEL PHARMACEUTICALS INC - Common Stock, par value $0.001 per share (RIGL). This represents 86% of the company’s total 18,470,418 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
66%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9.6% | 1,768,907 | +6.3% | 0% | $47,831,252 |
| ARMISTICE CAPITAL, LLC | 6.9% | 1,280,000 | +53% | 1.1% | $34,611,200 |
| STATE STREET CORP | 6.1% | 1,120,238 | +2.7% | 0% | $30,291,236 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 764,193 | 0% | 0% | $20,663,779 |
| ACADIAN ASSET MANAGEMENT LLC | 3.6% | 666,426 | +35% | 0.03% | $18,009,000 |
| LSV ASSET MANAGEMENT | 3.3% | 601,507 | +11% | 0.04% | $16,265,000 |
| MARSHALL WACE, LLP | 3.2% | 598,378 | -2.5% | 0.02% | $16,180,140 |
| AMERICAN CENTURY COMPANIES INC | 2.9% | 544,431 | +114% | 0.01% | $14,721,414 |
| D. E. Shaw & Co., Inc. | 2.4% | 445,678 | +5% | 0.01% | $12,051,133 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 440,626 | +3.8% | 0% | $11,917,730 |
| GOLDMAN SACHS GROUP INC | 2.4% | 439,101 | -35% | 0% | $11,873,291 |
| TWO SIGMA INVESTMENTS, LP | 2.2% | 405,807 | +50% | 0.01% | $10,973,021 |
| DIMENSIONAL FUND ADVISORS LP | 2.1% | 379,541 | +37% | 0% | $10,259,398 |
| Qube Research & Technologies Ltd | 1.9% | 343,897 | +19% | 0.01% | $9,298,975 |
| RENAISSANCE TECHNOLOGIES LLC | 1.8% | 338,441 | -37% | 0.01% | $9,151,445 |
| Nuveen, LLC | 1.8% | 337,427 | +30% | 0% | $9,124,026 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 264,410 | -39% | 0.01% | $7,149,646 |
| CM Management, LLC | 1.3% | 235,000 | +4.4% | 5.3% | $6,354,400 |
| GLOBEFLEX CAPITAL L P | 1.2% | 217,839 | 0% | 0.89% | $5,890,367 |
| Trexquant Investment LP | 1.2% | 216,410 | +9.8% | 0.04% | $5,851,726 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.96% | 176,850 | +19% | 0% | $4,782,024 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.91% | 167,342 | -60% | 0% | $4,524,928 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.82% | 151,311 | +148% | 0% | $3,891,719 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.8% | 147,535 | 0% | 0% | $3,989,346 |
| BANK OF AMERICA CORP /DE/ | 0.78% | 144,131 | +23% | 0% | $3,897,302 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 15,871,693 | $428,893,659 | -$17,595,270 | $27.04 | 148 |
| 2025 Q4 | 16,094,279 | $688,576,820 | +$63,536,235 | $42.83 | 185 |
| 2025 Q3 | 14,989,035 | $424,666,568 | +$32,448,563 | $28.33 | 164 |
| 2025 Q2 | 13,883,445 | $260,032,689 | +$336,299 | $18.73 | 121 |
| 2025 Q1 | 13,902,025 | $250,095,419 | +$32,047,743 | $17.99 | 118 |
| 2024 Q4 | 12,067,467 | $202,977,408 | +$2,514,731 | $16.82 | 114 |
| 2024 Q3 | 11,904,852 | $192,606,131 | +$27,253,219 | $16.18 | 87 |
| 2024 Q2 | 10,378,502 | $85,309,593 | +$85,148,446 | $8.22 | 80 |